Tracking tumor burden in people with NF1
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study looks for better ways to measure how much tumor activity people with neurofibromatosis type 1 (NF1) have over time. The goal is to develop “biomarkers,” which are test results that may help doctors track disease more easily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of neurofibromatosis type 1 (NF1)
- You are able to meet the NF1 diagnostic criteria (not just suspected)
- You are not pregnant at the screening visit
- You (or your parent/legal guardian, if needed) can understand and sign the informed consent form
- You are not affected by “mosaic” NF1 (a specific subtype)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study monitors people with neurofibromatosis type 1 (NF1) over time to watch for signs that their nerve tumors might turn into cancer. It helps researchers learn which tumors are more likely to change and may lead to better care.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
This study is looking for adults with NF1 who have had a plexiform neurofibroma. It aims to find better ways to detect tumors early, which could help with treatment decisions.
This study uses special MRI scans plus computer (AI) analysis to look for early, possibly cancer-related skin or tissue changes in children with neurofibromatosis type 1 (NF1). If it works, it could help doctors detect concerning changes earlier and plan care sooner.
This study checks whether patient surveys (questionnaires) can reliably measure symptoms and pain in people with NF1 who have plexiform neurofibromas. It helps create better tools for tracking how you feel and how treatments may affect quality of life.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.